Table 2.

Comparison of HDL sub-distribution in the HC, MCI, and AD groups, expressed as % or mg/dl

	Lipoprotein fractions (% of total HDL)			Lipoprotein fractions (mg/dl)
	HC	MCI	AD	HC	MCI	AD
HDL L	34.5±10.2	34.5±10.0	38.3±10.4	24.0±12.4	22.7±10.7	25.9±11.2
HDL I	53.9±6.8	54.0±6.1	53.1±7.4	34.9±7.6	33.5±6.0	34.5±8.4
HDL S	11.5±5.6	11.3±6.0	8.5±5.4	7.1±3.1	6.8±3.2	5.4±3.5
General linear model
	HDL Subdistribution expressed as %			HDL Subdistribution expressed as mg/dl
	Overall, p	Individual comparisons, p		Overall, p	Individual comparisons, p
HDL L	0.10		0.12
HDL I	0.21		0.56
HDL S	<0.001	HC-o versus MCI 0.77		<0.001	HC-o versus MCI 0.58
		HC-o versus AD < 0.001			HC-o versus AD < 0.001
		MCI versus AD 0.004			MCI versus AD 0.006

ANCOVA (analyses were adjusted for sex, age, site, and APOE ɛ4-carrier status) or non-parametric ANOVA (Kruskal-Wallis analysis) were used and regarded as significant when p < 0.05 (bold). When Kruskal-Wallis analysis was significant, individual comparison was performed using Mann-Whitney U Test and considered significant when p < 0.05 (bold). For HDL S (% and mg/dl), HDL L (mg/dl) and HDL I (mg/dl) non-parametric tests were used. Values are presented as mean±S.D.